Best Small-Cap Biotech Stocks 2026
Top 5 small-cap biotech stocks by fundamental score in 2026. Pipeline analysis, cash runway, and risk factors. Try free for 30 days.
Biotech is the highest-risk, highest-reward sector in small-cap investing — and the data confirms it. Among the 380+ small-cap biotech stocks in our universe, the median fundamental score is just 31/100, the lowest of any sector we track. Most are pre-revenue, cash-burning clinical-stage companies where binary FDA outcomes determine everything. Yet within that challenging landscape, a handful of small-cap biotech stocks stand out with genuinely strong fundamentals. Here are the top 5 by composite score, what the numbers show, and what the numbers don't.
Why Biotech Scores Lower Than Every Other Sector
Before reviewing the list, it helps to understand why biotech stocks systematically produce lower fundamental scores than industrials, technology, or consumer names. This isn't a flaw in the methodology — it reflects genuine structural differences.
| Metric | Typical Biotech Challenge |
|---|---|
| Cash Runway | Most companies are pre-profit and burning cash to fund trials |
| Revenue Growth | Many are pre-revenue or dependent on lumpy milestone payments |
| Gross Margin | Clinical-stage companies generate minimal revenue to build margin from |
| P/S Ratio | Valuations run high relative to early-stage revenue |
| Share Dilution | Frequent equity raises are standard to fund ongoing trials |
A biotech scoring 70+ sits further above its sector peers than an industrial company scoring 85+. Context matters when reading these scores. Use our screener to filter by sector and compare companies within the same peer group rather than across the full universe.
For a deeper look at how sector context shapes stock screening decisions, see our healthcare sector analysis.
Understanding Our Scoring Methodology for Biotech
The SmallCap Scanner composite score weights eight fundamental factors. For clinical-stage biotechs, revenue and margin metrics will score near zero — that's expected. The score still captures financial health through cash runway, debt levels, insider ownership, and dilution control. A pre-revenue company scoring 70+ has done something unusual: it has managed its balance sheet well enough to compensate for absent revenue.
Learn more about how our scoring model works and why cash runway receives heavy weighting in capital-intensive sectors.
Top 5 Small-Cap Biotech Stocks by Fundamental Score
1. Corcept Therapeutics (CORT) — Score: 91/100
| Metric | Value | Score |
|---|---|---|
| Revenue Growth | +38% YoY | 88/100 |
| Gross Margin | 78% | 85/100 |
| Cash Runway | Profitable | 100/100 |
| Debt/Equity | 0% | 100/100 |
| P/S Ratio | 8.2x | 42/100 |
| Insider Ownership | 7.8% | 65/100 |
| Share Dilution | +1.2% | 82/100 |
| Rule of 40 | 68 | 95/100 |
Corcept is an anomaly in biotech: a profitable, debt-free, rapidly growing specialty pharmaceutical company. Its lead drug Korlym treats Cushing's syndrome — a rare hormonal disorder caused by chronic elevated cortisol — and now generates over $700M in annual revenue. That revenue base funds both operations and R&D without requiring equity raises.
FDA Pipeline: Relacorilant, a next-generation selective cortisol modulator, is in Phase 3 trials for Cushing's syndrome. The PDUFA date is expected in late 2026. FDA approval would extend market exclusivity and potentially expand the addressable patient population beyond Korlym's current label. Trial details are available on ClinicalTrials.gov.
Risk: Single-product dependency remains the core concern. Korlym's patent protection and any generic entry are existential variables. Relacorilant approval is not a growth catalyst — it's a necessity for long-term thesis sustainability.
2. Catalyst Pharmaceuticals (CPRX) — Score: 89/100
| Metric | Value | Score |
|---|---|---|
| Revenue Growth | +22% YoY | 72/100 |
| Gross Margin | 91% | 98/100 |
| Cash Runway | Profitable | 100/100 |
| Debt/Equity | 0% | 100/100 |
| P/S Ratio | 5.4x | 55/100 |
| Insider Ownership | 4.2% | 48/100 |
| Share Dilution | -2.1% (buyback) | 100/100 |
| Rule of 40 | 62 | 92/100 |
Catalyst's Firdapse franchise in Lambert-Eaton Myasthenic Syndrome (LEMS) generates a 91% gross margin — among the highest in all of pharma, not just biotech. The company has moved beyond simply growing revenue: it is buying back shares, a capital allocation decision that signals discipline and confidence in the balance sheet.
FDA Pipeline: Catalyst is expanding its rare disease portfolio through internal R&D and potential acquisitions. Its strong cash position enables strategic M&A without dilution, which is the rare disease playbook done correctly. FDA approval history and drug label details are available through SEC EDGAR filings and FDA.gov.
Risk: LEMS is a small patient population by design. Sustained growth requires either expanding Firdapse's approved indications or successful M&A execution. Neither is guaranteed.
3. Iovance Biotherapeutics (IOVA) — Score: 84/100
| Metric | Value | Score |
|---|---|---|
| Revenue Growth | +312% YoY | 100/100 |
| Gross Margin | 58% | 62/100 |
| Cash Runway | 20 months | 58/100 |
| Debt/Equity | 15% | 88/100 |
| P/S Ratio | 3.7x | 62/100 |
| Insider Ownership | 2.8% | 35/100 |
| Share Dilution | +8.5% | 42/100 |
| Rule of 40 | 280 | 100/100 |
Iovance represents the commercial frontier of cell therapy. Its TIL (tumor-infiltrating lymphocyte) therapy Amtagvi is the first FDA-approved TIL therapy in history, targeting advanced melanoma patients who have exhausted prior treatment options. The commercial launch is ramping rapidly — 312% revenue growth is not a projection, it is the current trailing figure.
FDA Pipeline: Iovance is pursuing TIL therapy applications in non-small cell lung cancer and cervical cancer, both in advanced clinical stages. Each new indication could materially multiply the addressable patient population. Clinical trial status can be tracked at ClinicalTrials.gov and NIH's National Cancer Institute.
Risk: Manufacturing complexity is the binding constraint. TIL therapy requires patient-specific cell processing — each dose is manufactured from a biopsy of the individual patient's tumor. This limits scale in ways that conventional drug manufacturing does not face. At 20 months of cash runway, the commercial ramp needs to accelerate before the company requires additional capital. For more on evaluating runway in clinical-stage companies, see our guide on cash runway and small-cap survival.
4. Verona Pharma (VRNA) — Score: 78/100
| Metric | Value | Score |
|---|---|---|
| Revenue Growth | +185% YoY | 100/100 |
| Gross Margin | 82% | 90/100 |
| Cash Runway | 16 months | 48/100 |
| Debt/Equity | 28% | 78/100 |
| P/S Ratio | 12.5x | 22/100 |
| Insider Ownership | 5.5% | 55/100 |
| Share Dilution | +4.2% | 68/100 |
| Rule of 40 | 145 | 100/100 |
Verona Pharma's Ohtuvayre (ensifentrine) received FDA approval for COPD maintenance therapy — the first new mechanism of action approved for COPD in over a decade. The launch is tracking ahead of most comparable respiratory drug launches in terms of prescription velocity. That 185% revenue growth figure reflects a commercial product, not a projection.
FDA Pipeline: Verona is pursuing additional respiratory indications including asthma and cystic fibrosis. If either succeeds, the addressable market expands by an order of magnitude beyond COPD.
Risk: At 12.5x sales, the valuation prices in sustained aggressive growth. Cash runway of 16 months is the tightest on this list. If prescription growth decelerates, Verona will need to raise capital under less favorable conditions. The score reflects both the commercial momentum and the financial pressure simultaneously.
5. Nuvation Bio (NUVB) — Score: 71/100
| Metric | Value | Score |
|---|---|---|
| Revenue Growth | N/A (pre-revenue) | 0/100 |
| Gross Margin | N/A | 0/100 |
| Cash Runway | 42 months | 85/100 |
| Debt/Equity | 0% | 100/100 |
| P/S Ratio | N/A | 50/100 |
| Insider Ownership | 18.2% | 95/100 |
| Share Dilution | +1.8% | 78/100 |
| Rule of 40 | N/A | 30/100 |
Nuvation Bio is a pre-revenue biotech with a high fundamental score — a combination that requires explanation. The score is driven entirely by financial health metrics: 42 months of cash runway, zero debt, 18.2% insider ownership, and minimal dilution. The company is well-funded to advance its oncology pipeline without near-term capital pressure.
FDA Pipeline: Lead program taletrectinib targets ROS1-positive non-small cell lung cancer, a genetically defined patient subset with limited current treatment options. Phase 2 data has shown meaningful response rates. Regulatory submissions and clinical data are filed with FDA.gov and registered on ClinicalTrials.gov.
Risk: No approved products. No revenue. The entire thesis depends on clinical outcomes and regulatory decisions. What distinguishes Nuvation from the hundreds of other pre-revenue biotechs is the 42-month runway — the company has the capital and time to execute without being forced into dilutive raises at the worst moment.
How to Screen Biotech Small-Caps Effectively
Biotech requires different screening parameters than most sectors. Applying a standard 70+ score threshold will eliminate nearly the entire sector. A better approach:
1. Adjust your score threshold by sector. A biotech scoring 60+ is in the top quartile of the sector. The sector-relative percentile matters more than the absolute number.
2. Weight cash runway as the primary survival filter. In biotech, cash is survival. A company with 36+ months of runway has time to navigate setbacks. A company with 8 months does not. Sort by cash runway first, score second.
3. Separate commercial-stage from clinical-stage. Corcept and Catalyst have approved, revenue-generating products. Nuvation does not. The fundamental score captures part of this distinction through revenue and margin metrics, but it does not capture the full binary risk profile of clinical-stage companies. For a broader view of how healthcare sub-sectors compare, see our top 5 healthcare small-caps analysis.
4. Track binary events separately. FDA decisions, clinical trial data readouts, and partnership announcements can move biotech stocks 50%+ in a single session. The fundamental score does not predict these events — and it is not designed to. Binary event calendars are a separate research layer.
5. Check SEC filings directly. For any biotech on your watchlist, read the most recent 10-Q on SEC EDGAR before acting. The cash position, share count, and any ATM (at-the-market) offering activity in the footnotes will tell you more than the headline metrics.
Filter the full biotech universe by score, cash runway, and individual metrics using our screener.
What the Score Doesn't Capture
The composite score is a quantitative filter — it measures what is measurable. In biotech, several critical variables fall outside its scope:
- Pipeline depth: A company with three Phase 3 assets in separate indications has a fundamentally different risk profile than one with a single trial. The score does not distinguish between them.
- Management track record: Serial biotech executives who have navigated prior FDA approvals are a meaningful variable. The score does not weight this.
- Intellectual property position: Patent breadth, exclusivity timelines, and Freedom to Operate analyses are legal assessments that no scoring model captures cleanly.
- Competitive landscape shifts: A competitor approval in the same indication can immediately change the market dynamics for any company on this list.
Use the score as the first filter. Use the research brief, SEC filings, and FDA approval history as the second layer.
This article is for informational purposes only and does not constitute financial advice. Biotech investing carries significant risk including the potential for total loss of capital. All five companies listed carry company-specific and sector-level risks not fully captured by any quantitative scoring model. Always conduct your own due diligence before making investment decisions.